Abstract: The disclosure concerns a prognostic method for determining at least one, or a combination, of the following: time to first treatment, response to treatment or overall survival for a patient presenting with a disease including or characterized by telomere shortening, including an assessment of the longest mean telomere length at which telomere end-end fusion events can be detected and then a determination of the mean telomere length in the fusogenic range (i.e. the range below that mean telomere length at which telomere end-end fusion events can be detected) and the subsequent use of the mean telomere length in the fusogenic range as a prognostic indicator.

Abstract: The present application relates to compounds of any one of Formulae I, Ia, Ib, Ic, Id, Ie, and If. Compounds of Formula (I) have the structure: wherein A, B, W, Y, Z, R2, R4, R5, R6, Rq and q are as defined herein. The compounds can be used as inhibitors of Bcl-3 and can be used for the treatment of cancer, particularly metastatic cancer.

Abstract: A method is provided for detecting alkylating agents, the method comprising bringing together a first solvent, one or more surfactants, a base, a reagent comprising a nucleophilic nitrogen atom, and a suspected alkylating agent. A device suitable for putting said method into effect is also provided.

Abstract: The invention relates to a device for use in skin improvement or repair, including promoting hair growth, comprising the use of microneedles for the transplantation of cells and a method employing the use of same.

Abstract: Method for identifying a bacterial infection The present application concerns a method for identifying the nature of a bacterial infection from a peritoneal sample, in particular, whether it is a Gram-negative or Gram-positive infection, based upon the determination of one or more cellular and/or humoral markers in a sample.

Abstract: A method of producing at least one compound comprising an alkenyl group from at least one compound comprising an alkyl group having two or more carbon atoms, the method comprising: (i) Providing a mixture comprising carbon dioxide and at least one compound comprising an alkyl group having two or more carbon atoms; and (ii) Contacting said mixture with a catalyst comprising one or both of palladium and platinum and one or more lanthanide, thereby converting at least a portion of the at least one compound comprising an alkyl group having two or more carbon atoms into a compound comprising an alkenyl group, the total of the weight of the palladium and/or platinum being more than 0.1 wt % of the catalyst.

Abstract: Provided are phosphoramidate nucleoside compounds of Formula (I), or pharmaceutically acceptable salts or esters or solvates thereof, useful in the treatment of cancer, viral infections and other diseases: Also provided is a process for the synthesis of the compounds of Formula (I) where a desired enantiomer, having regard to the asymmetric chiral center of the phosphorus atom P, is provided in an enriched amount. The process comprises admixing a nucleoside with a phosphorochloridate in the presence of a catalyst comprising a metal salt selected from the group consisting of salts of Cu, Fe, La and Yb.

Abstract: The present application relates to therapeutics and pharmaceutical compositions, their use and also methods for preventing post-traumatic osteoarthritis, early or late stage, using compounds which inhibit either, or both, AMPA and KA glutamate receptors (Glu Rs).

Abstract: The invention relates to a novel antibiotic delivery vehicle for impregnating bone cement wherein said vehicle is an antibiotic encapsulated liposome having a block co-polymer on its surface; a method for the manufacture of a bone cement impregnated with antibiotic or a mixture of antibiotics using said vehicle; and also a novel bone cement made therewith and/or thereby.

Abstract: The present invention relates to methods of assessing whether a subject has or is likely to develop a neurodegenerative disease comprising determining whether the subject has a mutation in the C9orf72 gene wherein said mutation prevents or disrupts C9orf72 expression relative to expression in a reference from subjects without the mutation.

Abstract: Described herein are nitrated lipids and methods of making and using the nitrated lipids.

Abstract: A calcium/cation-sensing receptor (CaSR) antagonist to treat an inflammatory lung disorder is described. Methods of treatment including the antagonist, combination therapeutics including the antagonist and at least one other agent, and nebulizers or inhalers including the antagonist are also described.

Abstract: The invention concerns a cartridge for an inhalation device for delivering anaesthetic to a human or animal wherein anaesthetic in the cartridge is dispersed in an anaesthetic control release medium; an inhalation device for use with the cartridge and a formulation including at least one selected anaesthetic and anaesthetic control release medium.

Abstract: Molecular target for healing or treating wounds and, in particular chronic, human wounds, are described. The molecular target is PTPRK, or a protein 50% homologous therewith, and which retains the same activity as PTPRK protein. Further, methods and novel therapeutics are described for treating said wounds.

Abstract: The present application relates to compounds of any one of Formulae I, Ia, Ib, Ic, Id, Ie, and If. Compounds of Formula (I) have the structure: wherein A, B, W, Y, Z, R2, R4, R5, R6, Rq and q are as defined herein. The compounds can be used as inhibitors of Bcl-3 and can be used for the treatment of cancer, particularly metastatic cancer.

Abstract: Described herein are nitrated lipids and methods of making and using the nitrated lipids.

Abstract: A catalyst is provided, the catalyst comprising rods having mean length of 100 microns or less, the rods comprising a metal molybdate or tungstate, the metal being selected from the group consisting of iron, manganese, nickel, chromium, vanadium, aluminum, silver, titanium, copper, bismuth, and cobalt. A method of making such a catalyst is also provided.

Abstract: A method is provided for detecting sulphur-containing species (such as thiophosphorous esters, in particular phosphorylating agents), in which a suspected sulphur-containing species is brought into contact with a tetrazolium compound in the presence of base, typically at a pH of at least 8. A device, kit and tetrazolium compounds for use in such a method are also disclosed.

Abstract: A compound for use in the treatment or prophylaxis of viral infections such, for example as chicken pox or shingles caused by the Varicella Zoster virus, said compound having the general formula (II): wherein X is O, S, NH or CH2, Y is O, S or NH, Z is O, S or CH2, R1 is C1-6 alkyl, preferably n-alkyl, e.g., n-pentyl or n-hexyl, and one of R2 and R3 is OH, and the other of R3 and R2 is a neutral, non-polar amino acid moiety, or a pharmaceutically acceptable salt or hydrate thereof. Said neutral, non-polar amino acid moiety R2 or R3 may be (IV): in which R4, R5, R6 and R7 are each independently H or C1-2 alkyl. In preferred embodiments, one of R2 or R3 is valine, leucine, isoleucine or alanine, particularly valine.

Abstract: A process for the complete or partial oxygenation of hydrocarbons comprises contacting a C1-C8 hydrocarbon, molecular oxygen, and hydrogen peroxide, in the presence of water and a heterogeneous catalyst, under conditions suitable to convert the C1-C8 hydrocarbon to at least one corresponding C1-C8 oxygenate product, wherein the heterogeneous catalyst provides confinement and contains both Brønsted-Lowry acid centers and Lewis acid centers. The reaction may be carried out at a temperature ranging from 2° C. to 90° C. The use of molecular oxygen increases the economic attractiveness of the process while also improving yield.